CD34 and head and neck squamous cell carcinoma: This trial with HNSCC patients showed that 1,25(OH)2D3 diminishes peripheral blood and intratumoral levels of immunosuppressive CD34+ cells and increases levels of mature dendritic cells, as identified by positive staining for CD‐LAMP (Figure 5) [15,45].